According to filings with the U.S. Securities and Exchange Commission, Sprout2 dba Sprout Pharmaceuticals is raising $10,000,000.00 in new funding. Sources indicate that as part of senior management Chief Financial Officer, Matthew Petzold played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Sprout2 dba Sprout Pharmaceuticals
Were committed to breakthrough firsts in womens sexual health. Novel ideas fuel our entrepreneurial passion. At Sprout, we celebrate ownership, boldness, quirkiness, learning, family and appreciation. They are central to what we stand for and what were trying to collectively accomplish. We looked the pharma industry right in the eye and said: Now, its our turn. Millions of women suffer from Hypoactive (low) Sexual Desire Disorder (HSDD), and they deserve to be heard. We opened bedroom doors and welcomed a long overdue conversation about women and sex. When our product launched, there were 26 different treatments for male sexual dysfunction available and none for women. So we made it our obligation to break through with the first. We changed the game for women and haven’t stopped making noise since.

To learn more about Sprout2 dba Sprout Pharmaceuticals, visit http://sproutpharmaceuticals.com/

Contact:
Matthew Petzold, Chief Financial Officer
844-746-5745
https://www.linkedin.com/in/matthew-petzold-075162/

SOURCE: http://www.intelligence360.io
Copyright (c) 2023 SI360 Inc. All rights reserved.